Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-

Company Name:	Shanghai Beckham Medical Technology Co., Ltd
Tel:	13816613772
Email:	huahero21@sina.com

Company Name:	Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd
Tel:	15317229551
Email:	15151849396@163.com

Company Name:	Hangzhou Taorui Biotechnology Co., Ltd
Tel:	QQ1259737804 15268198094
Email:	sales@torreybio.com

Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- manufacturers

Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- Basic information

Product Name:	Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-
Synonyms:	Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-;ELOVL1-IN-27;1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide;ELOVL1-IN-1;chain,inhibit,adrenoleukodystrophy,Inhibitor,ELOVL1IN1,ALD,fatty,ELOVL-1-IN-1,acid,ELOVL1 IN 1,long;ELOVL1-27;ELOVL1-IN-1, 10 mM in DMSO
CAS:	2227482-41-7
MF:	C18H14F2N4O
MW:	340.33
EINECS:
Product Categories:
Mol File:	2227482-41-7.mol

Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- Chemical Properties

Boiling point	584.1±50.0 °C(Predicted)
density	1.40±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMF: insol; DMSO: 2 mg/ml; Ethanol: insol; PBS (pH 7.2): insol
form	A crystalline solid
pka	12.79±0.20(Predicted)
color	White to off-white

Safety Information

MSDS Information

Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- Usage And Synthesis

Uses	ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1].
Biological Activity	ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1]. ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1]. ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1].
in vivo	ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)^[1].
References	[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1.

Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- Preparation Products And Raw materials

Tag:Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-(2227482-41-7) Related Product Information

Morpholine, 2-phenyl-4-[6-[[cis-3-(1H-pyrazol-1-yl)cyclobutyl]oxy]-4-pyrimidinyl]-, (2S)- AICAR 1H-Imidazole-4-carboxamide, 5-methyl-N-(1-methyl-1H-pyrazol-3-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]- Orlistat CERULENIN 3-(pyridin-2-ylsulfonyl)-N-(4-(trifluoroMethyl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxaMide